Who
A. Brian Davis
Director
Company insider
Files Form 4 as: Director, Grace Therapeutics; Chief Financial Officer, Verrica Pharmaceuticals; Chief Financial Officer, Strongbridge Biopharma; Chf. Fin. Offr, VP Fin., Tengion; Sr. Vice President and CFO, Neose Technologies.
In numbers
- Trades disclosed
- 35
- Buys
- 2
- Sells
- 0
- Bought
- $99K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 30 Jan 2006
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | — | filing |
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | — | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Dec 2023filed 20 Dec 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 4 Jun 2021filed 7 Jun 2021 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $49K5,000 at $9.89 | filing |
| 1 Mar 2021filed 3 Mar 2021 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 13 Aug 2020filed 17 Aug 2020 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $49K7,900 at $6.24 | filing |
| 27 Feb 2020filed 2 Mar 2020 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 18 Oct 2019filed 21 Oct 2019 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 20 Feb 2019filed 22 Feb 2019 | Strongbridge Biopharmaoption or derivative | SEC FORM 4 Code A | —108,500 at $0.00 | filing |
| 20 Feb 2019filed 22 Feb 2019 | Strongbridge Biopharma | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 26 Feb 2018filed 28 Feb 2018 | Strongbridge Biopharma | SEC FORM 4 Code F | $57K8,696 at $6.60 | filing |
| 5 Feb 2018filed 6 Feb 2018 | Strongbridge Biopharmaoption or derivative | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Mar 2013filed 6 Mar 2013 | Tengion | SEC FORM 4 Code F | $224179 at $1.25 | filing |
| 4 Mar 2013filed 6 Mar 2013 | Tengion | SEC FORM 4 Code F | $654523 at $1.25 | filing |
| 16 Feb 2012filed 21 Feb 2012 | Tengionoption or derivative | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 16 Feb 2012filed 21 Feb 2012 | Tengion | SEC FORM 4 Code A | —68,333 at $0.00 | filing |
| 11 May 2011filed 13 May 2011 | Tengionoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.